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Summary
Objectives: To describe leprosy-related disabilities, we performed a census
including people affected by leprosy in 78 municipalities of Tocantins state in
northern Brazil. The study consisted of a review of patient charts, structured
questionnaires, and clinical examinations for disabilities of eyes, hands, and feet
(August–December 2009), according to WHO standards.
Results: A total of 910 individuals diagnosed from 2006 to 2008 were included
(clinical examination and application of questionnaires), but information from patient
charts was not available in all cases, resulting in different denominators. The majority
(783/858; 91·3%) had completed multidrug therapy. The most common clinical
findings included: enlarged/painful peripheral nerves (412/910, 45·3%), namely of
ulnar (207; 22·7%), posterior tibial (196; 21·6%), peroneal (186; 20·5%), and radial
cutaneous nerves (166; 18·2%); reduction/loss of sensibility 201/907 (22·2%) and
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reduced motor function (185/906, 20·4%). At diagnosis, 142/629 (22·6%) had Grade
1 disability (G1D), and 28/629 (4·5%) had Grade 2 disability (G2D). At the time of the
study, 178/910 (19·6%) presented with G1D, and 84/910 (9·2%) with G2D. Disability
grading was significantly higher in males (P , 0·01). Subjects with G2D showed
claw hands (26; 2·9%), followed by plantar ulcers (23; 2·5%), abrasion/excoriation on
the foot (12; 1·3%), claw foot (7; 0·7%), and drop foot (7; 0·7%).
Conclusions: Leprosy-related disabilities were common in a highly endemic area.
Prevention and rehabilitation measures, especially after release from treatment,
should be intensified by the primary health care system. Policy makers need to be
aware of an ongoing demand for leprosy control programmes, even in a world of
constantly reducing leprosy detection.
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Introduction
Leprosy is one of the most ancient infectious diseases of humanity, but still poses a health
threat in many countries, with most cases occurring in India, Brazil and Indonesia (in 2015
worldwide: 210,758, Brazil: 26,395).1 Despite decreased leprosy incidence during recent
years, peripheral neuropathy and physical disabilities caused by Mycobacterium leprae
continue to be a major problem, as they may persist for many years and even worsen after
release from treatment (RFT). The proportion of people with visible deformity and/or severe
visual impairment (i.e. WHO Grade 2 disability – G2D) among newly detected leprosy cases
increased worldwide in recent years, from 3·7% (2005) to 6·6% (2015), and in Brazil from
5·8% (2005) to 6·6% (2015).1 – 3 A similar upward trend of the rate of newly detected cases
with G2D (7·2% in 2015) has been observed in Tocantins State in Brazil’s North region,
where this study was performed.4
In the current WHO Global Leprosy Strategy for 2016–2020, the reduction of the rate of
newly diagnosed leprosy patients with G2D to less than one per million population is one of
the aims.5 This indicator for late diagnosis can be reduced by improving coverage and access
in endemic areas and targeting case detection among high risk groups.
The present study forms part of a multidisciplinary epidemiological investigation called
IntegraHans MAPATOPI, performed in a hyperendemic region in North Brazil. We present
the results of clinical examinations, review of patient charts, and structured questionnaires,
regarding impairments and disabilities in a population from 78 municipalities.
Methods
The Brazilian General Coordination of Leprosy & Diseases in Elimination (Coordenac¸a˜o
Geral de Hansenı´ase e Doenc¸as em Eliminac¸a˜o – CGHDE) of the Ministry of Health
identified several years ago 10 high risk leprosy clusters, in order to focus and intensify
prevention and control measures.6 The present study is a cross-sectional study performed in
the so-called cluster 1, within the realm of the IntegraHans MAPATOPI project, a major
project performed in the four Brazilian states Maranha˜o [MA], Para´ [PA], Tocantins [TO] and
Piauı´ [PI].7 – 9 MAPATOPI includes studies on the epidemiological, clinical, psychosocial,
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and operational determinants of leprosy. Details of this project have been published
previously elsewhere.6,9,10
STUDY AREA AND POPULATION
Tocantins, the most recent state of the Brazilian Federation (created in 1988), is located in the
central savannah region. The state is subdivided into 139 municipalities with a total
population of 1·5 million.4 Tocantins is considered hyperendemic for leprosy (58·08 new
cases/100,000 inhabitants, 2015).4
The study was performed in a census population of 78 municipalities of northern
Tocantins that formed part of the high risk cluster 1.10,11 The target population included all
individuals newly diagnosed with leprosy from 2006–2008, living and notified as leprosy
cases in the study area. Leprosy cases were identified through the electronic database of the
National Information System for Notifiable Diseases (Sistema de Informaca˜o de Agravos de
Notificac¸a˜o – SINAN).11 If during field visits patients were identified in the local records that
had not been notified in SINAN, we included them in the study.
We did not include the municipality of Araguaı´na, which forms part of cluster 1, a major
city in the region with about 120,000 inhabitants. Araguaı´na has a leprosy reference clinic and
shows different characteristics, as compared to the other smaller municipalities that share
mainly rural characteristics. The results from Araguaı´na (147 leprosy-affected individuals)
have been published elsewhere.12,13
We excluded those who moved to municipalities outside the endemic cluster, and subjects
with mental disabilities or other pathologies, such as anxiety disorder or alcohol abuse, which may
interact with clinical examinations or interviews. Relapsed leprosy cases were also excluded.
STUDY DESIGN, VARIABLES AND DATA COLLECTION
The census included all leprosy patients of the study area matching the inclusion criteria. Data
collection included review of patient charts, clinical examinations, and the application of
structured questionnaires.
Variables included demographic information (age, sex, municipality of residence), and
clinical data (clinical form, operational classification, disability grade at diagnosis, mode of
case detection, date of diagnosis, date of release from treatment and date of last appearance at
the health center for treatment). WHO disability grading was based on examinations of eyes,
hands and feet, ranging from 0–2.14 In detail, the following criteria based on WHO
definitions were used - G0D: no anesthesia and no visible damage to eyes, hands and feet;
G1D: loss of protective sensibility of eyes, hands and/or feet, without visible damage or
deformities; G2D: deformities and/or visible damage to the eyes (shown by lagophthalmos
and/or ectropion, trichiasis, corneal opacity, visual acuity less than 0·1 or difficulty counting
fingers at 6 meters), visible damage to hands or feet (shown by ulcerations and/or traumatic
injuries, resorption, ulcers, drop hand, claw hand or foot, drop foot, ankle contracture). As
usual in Brazil, sensibility of eyes was assessed under field conditions, and G1D included
reduced corneal sensation.
In close cooperation with the Tocantins State Health Secretariat and the Municipality
Health Secretariats, field visits were coordinated; they took place from August to December
2009. Previous to field visits, the Municipal Health Secretariats were informed about the
timeframe when the team would perform data collection.
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During field visits, first the patient charts and the local notification records were reviewed
regarding clinical variables. Then, community health agents invited study participants to be
interviewed and examined at the health care centres. If individuals after several attempts did
not present at the health care centres, we performed home visits accompanied by local
community health agents, with direct individual approach to avoid stigma. Some of them had
not spoken about their leprosy diagnosis with their families or neighbours.
Data were collected using pre-tested structured questionnaires for data collection.
Clinical examinations were performed according to WHO and Brazilian MoH standards15,16
and focused on body regions, which are usually infected by leprosy: nose, eyes, upper and
lower extremities. The nose was examined with a lamp for leprosy related-lesions
(perforation of the nasal septum, dryness). Visual acuity was tested using Snellen charts.
Sensibility and peripheral nerve testing was performed (eyes, hands, feet) and peripheral
nerves of upper and lower extremities (ulnar, median, radial cutaneous, peroneal and
posterior tibial nerves) were palpated, as described in detail elsewhere.17
Corneal sensation was tested with a standard dental floss applied on the lateral lower
quadrant of the cornea. The Semmes-Weinstein monofilament kit was used to test the
sensitivity of hands and feet - six sensory sites on the palmar surface of the hands (three ulnar
and three median nerve-innervated areas) and nine topographic sites of the feet.16 G1D
sensory disability was defined if the 2g filament (i.e. the third of the six monofilaments) was
not felt, and/or if there was corneal sensory loss.
We applied a voluntary muscle strength test to verify the function of the peripheral motor
nerves, with the categories strong, weak and paralysed for eyelid closure, finger and thumb
abduction, fifth finger intrinsic position, wrist extension, extension of the hallux and
dorsiflexion of the foot.
To reduce inter-observer variation, all questionnaires and clinical examinations were
applied by previously trained field investigators who were constantly supervised during data
collection. Extensive pre-tests were performed under supervision.
DATA ENTRY AND ANALYSIS
Data were entered twice using Microsoft Office Accessw 7 (for clinical data) and Epi Info
Software Version 3.5.1 (Centers for Disease Control and Prevention, Atlanta USA) for data
from questionnaires and examinations. They were cross-checked, and entry-related errors
were corrected. Then, a unique database including all information sources was created.
Similar answers to open-ended questions were grouped and categorised. The data were
analysed using StataSEw (Version 9.1 for Windows, StataCorp LP, College Station, USA).
Variables are presented as absolute numbers and relative frequencies. We applied Fisher’s
exact test to estimate the significance of the difference of relative frequencies.
ETHICS
The study was approved by the Ethical Review Boards of the Federal University of Ceara´
(Fortaleza, Brazil) and of the Lutheran University of Palmas (Tocantins, Brazil). The study
and field research were permitted by the State Health Secretariat of Tocantins, by the National
Leprosy Control Program, and by the involved municipalities. Informed written consent was
obtained from study participants. The interviews took place in separated rooms to protect
privacy. If there were any clinical findings that required further diagnosis or treatment,
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participants were referred to the professionals of the local health centre for treatment or other
examinations.
Results
Of the target population of 1,488 people from 78 municipalities, 910 (61·2%) subjects of 74
municipalities were included in data analysis. Four municipalities had not notified any case;
549 (36·9%) subjects of the other municipalities had moved to another city outside the
endemic cluster, were not met even after home visits or were not known at the local health
centres. In 13 (0·9%) individuals, clinical examinations or the questionnaires were
incomplete, and another four (0·3%) refused clinical examination. In addition, eight people
(0·5%) did not give their consent to be included in the study. We excluded another four people
(0·3%), who had not understood the instructions.
The majority of study participants (783/858; 91·3%) had completed multidrug therapy.
The clinical information at diagnosis (clinical form, operational classification and disability
grading) collected from the patient health records was often incomplete, resulting in different
denominators: 745 (81·9%) with information on clinical form, 864 (94·9%) with information
on operational classification, and only 629 (68·4%) with information on disability grading.
Of the total of 910 participants, 478 (52·5%) were males; the age ranged from 5 to 98
years (mean ¼ 41·9 years; standard deviation: 18·6 years); 217 (23·5%) were illiterates, and
250 (27·5%) were living in rural areas. The majority (785; 91·3%) had been released after
MDT at the time of the study. A total of 483 (55·9%) had been classified as paucibacillary
(PB), and 381 (44·1%) as multibacillary (MB). The most common clinical form was
indeterminate (282; 37·4 %), followed by borderline disease (233; 30·9%), and tuberculoid
form (151; 20·0%).
At the moment of diagnosis, 142/629 (22·0%) had been graded with G1D, and 28/629
(4·4%) with G2D (Table 1). The clinical examination within the realm of the study revealed
178/910 (19·6%) of cases with G1D and 84/910 (9·2%) of G2D.
Details of the clinical examination are presented in Table 2.
Table 1. Grade of disability at physical examination during study, and at diagnosis, total number and stratified by
gender (n ¼ 910, but complete data not available in all cases)
Total Male Female
N (%) N (%) N (%) P-value
Grade of disability at diagnosis (patients’ charts)
Grade 0 459 (73·0) 222 (68·7) 237 (77·5) 0·02
Grade 1 142 (22·6) 81 (25·1) 61 (19·9)
Grade 2 28 (4·4) 20 (6·2) 8 (2·6)
Grade of disability during study (clinical examination)
Grade 0 648 (71·2) 301 (63·0) 347 (80·3) ,0·01
Grade 1 178 (19·6) 117 (24·5) 61 (14·1)
Grade 2 84 (9·2) 60 (12·5) 24 (5·6)
Dark grey: Distribution of females with G0D (diagnosis – time of study).
Light grey: Distribution of males with G0D (diagnosis – time of study).
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Table 2. General physical examination of the population during the study, total number and stratified by gender
(n ¼ 910, but complete data not available in all cases)
Total Males Females
N (%) N (%) N (%) P-value
Nasal examination
Symptoms relating to nose
Yes 81 (8·9) 40 (8·4) 41 (9·5) 0·56
No 829 (91·1) 438 (91·6) 391 (90·5)
Signs - lesions and dryness
Yes 54 (5·9) 29 (6·1) 25 (5·8) 0·89
No 856 (94·1) 449 (93·9) 407 (94·2)
Ocular examination
Symptoms related to eyes
Yes 324 (35·6) 162 (33·9) 162 (37·5) 0·27
No 586 (64·4) 316 (66·1) 270 (62·5)
Signs - corneal sensibility; reduction or loss of
sensibility on both eyes*
Yes 70 (7·7) 46 (9·6) 24 (5·6) 0·03
No 838 (92·3) 431 (90·4) 407 (94·4)
Reduction of visual acuity (,0·1) or difficulty
counting fingers at 6 meters
Yes 50 (5·5) 31 (6·5) 19 (4·4) 0·39
No 860 (94·5) 447 (93·5) 413 (95·6)
Lid closure (Facial nerve)
Weak/paralysed 30 (3·3) 21 (4·4) 9 (2·1) 0·06
Intact 880 (96·7) 457 (95·6) 423 (97·9)
Ocular findings*
Yes 208 (22·9) 130 (27·3) 78 (18·1) ,0·01
No 699 (77·1) 347 (72·7) 352 (81·9)
Examination of the upper extremities - symptoms
Yes 363 (39·3) 184 (38·5) 179 (41·4) 0·38
No 547 (60·7) 294 (61·5) 253 (58·9)
Evaluation of strength - reduced or paralysed
on both hands*
Yes 148 (16·3) 94 (19·7) 54 (12·5) ,0·01
No 760 (83·7) 382 (80·3) 378 (87·5)
Abduction of digit V (Ulnar nerve)*
Reduced 115 (12·7) 68 (14·3) 47 (10·9) 0·02
Paralysed 19 (2·1) 15 (3·2) 4 (0·9)
Intense 774 (85·2) 393 (82·5) 381 (88·2)
Abduction of thumb (Median nerve)*
Reduced 80 (8·8) 50 (10·5) 30 (6·9) 0·12
Paralysed 6 (0·7) 4 (0·8) 2 (0·5)
Intense 823 (90·5) 423 (88·7) 400 (92·6)
Extension of the fist (Radial nerve)*
Reduced 42 (4·6) 28 (5·9) 14 (3·2) 0·02
Paralysed 4 (0·4) 4 (0·8) 0
Intense 863 (95·0) 445 (93·3) 418 (96·8)
Nerve Palpation - painful or tender nerve -
upper extremities
Yes 302 (33·2) 187 (39·1) 115 (26·6) ,0·01
No 608 (66·8) 291 (60·9) 317 (73·4)
Ulnar nerve
Yes 207 (22·7) 138 (28·9) 69 (16·0) , 0·01
No 703 (77·3) 340 (71·1) 363 (84·0)
Median nerve
Yes 109 (12·0) 68 (14·2) 41 (9·5) 0·03
No 801 (88·0) 410 (85·8) 391 (90·5)
Radial nerve
Yes 166 (18·2) 101 (21·1) 65 (15·1) 0·02
No 744 (81·8) 377 (78·9) 367 (84·9)
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Table 2. Continued
Total Males Females
N (%) N (%) N (%) P-value
Evaluation of sensibility - reduction or loss of
sensibility - both hands
Yes 59 (6·5) 41 (8·6) 18 (4·2) ,0·01
No 851 (93·5) 437 (914) 414 (95·8)
Ulnar nerve*
Yes 58 (6·4) 41 (8·6) 17 (3·9) ,0·01
No 852 (93·6) 437 (91·4) 415 (96·1)
Median nerve
Yes 40 (4·4) 27 (5·7) 13 (3·0) 0·07
No 870 (95·6) 451 (94·3) 419 (97·0)
Examination of the feet - symptoms*
Yes 429 (47·1) 222 (46·4) 207 (47·9) 0·69
No 479 (52·9) 256 (53·6) 225 (52·1)
Evaluation of strength on both feet*
Reduced or paralysed 100 (11·0) 59 (12·4) 41 (9·5) 0·17
Intense 808 (89·0) 417 (87·6) 391 (90·5)
Extension of the digit I (Fibular nerve)*
Reduced 85 (9·4) 50 (10·5) 35 (8·1) 0·06
Paralysed 8 (0·9) 7 (1·5) 1 (0·2)
Intense 815 (89·7) 419 (88·0) 396 (91·7)
Dorsiflexion of the foot (Fibular nerve)*
Reduced 48 (5·3) 29 (6·1) 19 (4·4) ,0·01
Paralysed 9 (1·0) 9 (1·9) 0
Intense 852 (93·7) 439 (92·0) 413 (95·6)
Nerve palpation - painful or tender nerve -
lower extremities*
Yes 281 (30·9) 161 (33·8) 120 (27·8) 0·05
No 627 (69·1) 315 (66·2) 312 (72·2)
Tibial posterior nerve*
Yes 196 (21·6) 104 (21·8) 92 (21·3) 0·87
No 712 (78·4) 372 (78·2) 340 (78·7)
Fibular nerve*
Yes 186 (20·5) 117 (24·5) 69 (16·0) ,0·01
No 723 (79·5) 360 (75·5) 363 (84·0)
Evaluation of sensibility - reduction or loss of
sensibility on both feet*
Yes 194 (21·4) 136 (28·6) 58 (13·4) ,0·01
No 714 (78·6) 340 (71·4) 374 (86·6)
Clinical findings – eyes*
Yes 208 (22·9) 130 (27·3) 78 (18·1) ,0·01
No 699 (77·1) 347 (72·7) 352 (81·9)
Upper extremities*
Yes 160 (17·6) 100 (21·1) 60 (13·9) ,0·01
No 747 (82·4) 375 (78·9) 372 (86·1)
Lower extremities*
Yes 233 (25·7) 149 (31·4) 84 (19·4) ,0·01
No 674 (74·3) 326 (68·6) 348 (80·6)
Clinical findings on upper extremities and/or
lower extremities and/or eyes
Yes 405 (44·5) 246 (51·5) 159 (36·8) ,0·01
No 505 (55·5) 232 (48·5) 273 (63·2)
Clinical findings on upper and lower extremities
and eyes
Yes 38 (4·2) 28 (5·9) 10 (2·3) ,0·01
No 872 (95·8) 450 (94·1) 422 (97·7)
*data not available in all cases.
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In general, disabilities detected in this study were more common in males, especially
regarding visual acuity, plantar and palmar sensibility, muscle strength of the hands and
palpation of the nerves of the upper extremities. Disability grading was significantly higher in
males (P , 0·01; Table 1).
Table 3 details the findings of physical disabilities. Most subjects with G2D showed
strongly limited visual acuity (,0·1), followed by claw hands, corneal opacity and plantar
ulcers. Table 4 details the GD at diagnosis, as compared to the assessment during the study;
18·2% presented with a higher GD than at diagnosis, whereas 15·9% improved. The
remaining 65·9% maintained their GD, most of them with G0D.
Figures 1a and 1b depict the distribution of subjects with G1D and G2D, stratified by
gender and age, at the time of the study. Both genders presented an increase with higher age.
Discussion
This cross-sectional study shows that more than a quarter of the subjects from a
hyperendemic area suffered from leprosy-related impairment and that 10% presented visible
disabilities (G2D). Tendered or painful nerves were the most common pathological findings,
and related to nerve damage,18,19 which is an indicator for the development of present and
future disabilities.12 The occurrence of damaged peripheral nerves is linked to increased
disability, as recently demonstrated in a Brazilian cohort study.18 At the time of the study,
G2D had increased considerably. As a chronic condition, the sensory and nerve evaluation in
leprosy cases should be performed as standard at every examination: at time of diagnosis and
at time of every examination after diagnosis as well as examination after RFT.
Table 3. Disabilities of hands and feet, as detected at physical examination during study, total number and stratified
by gender (n ¼ 910, but complete data not available in all cases)
Total Males Females
N (%) N (%) N (%) P-value
Eyes 63/910 (6·9) 41/437 (8·6) 22/410 (5·1) 0·05
Corneal opacity 23/909 (2·5) 17/460 (3·6) 6/426 (1·4) 0·06
Trichiasis 1/910 (0·1) 1/476 (0·2) 0 1·00
Reduction of visual acuity less than
0·1 or difficulty counting fingers at
6 meters
50/909 (5·5) 31/446 (6·5) 19/413 (4·4) 0·19
Hands 26/910 (2·9) 20/458 (4·2) 6/426 (1·4) 0·02
Claw hand 26/910 (2·9) 0/458 (4·2) 6/426 (1·4) 0·02
Abrasion/excoriation 6/910 (0·7) 6/472 (1·3) 0 0·03
Palmar ulcer 2/910 (0·2) 2/476 (0·4) 0 0·50
Drop hand 3/910 (0·3) 3/475 (0·6) 0 0·25
Feet 35/910 (3·9) 23/455 (4·8) 12/420 (2·8) 0·12
Plantar ulcer 23/910 (2·5) 16/462 (3·5) 7/425 (1·6) 0·14
Abrasion/excoriation 12/910 (1·3) 7/471 (1·5) 5/427 (1·2) 0·78
Claw foot 7/910 (0·8) 2/476 (0·4) 5/427 (1·2) 0·27
Drop foot 7/910 (0·8) 7/471 (1·5) 0 0·02
Eyes, lower and/or upper extremities 110/910 (12·1) 74/404 (15·5) 36/396 (8·3) ,0·01
Eyes, lower and upper extremities 2/910 (0·2) 1/477 (0·2) 1/431 (0·2) 1·00
Lower and/or upper extremities 54/910 (5·9) 39/439 (8·2) 15/417 (3·5) ,0·01
Lower and upper extremities 7/910 (0·8) 4/474 (0·8) 3/429 (0·7) 1·00
Disabilities caused by leprosy in Brazil 527
The ulnar nerve is usually the most commonly affected peripheral nerve, followed by the
tibial nerve.20,21 In some studies most of the impairments were seen on the feet, followed by the
hands and eyes.12,22 Independent of the topographic location, prevention measures including
self-care activities have to be applied during the entire lifetime to prevent further disabilities.20
By intensification of the Brazilian Leprosy Control Program, a continuing reduction of newly
detected cases of leprosy has been achieved. These efforts should necessarily be integrated with
programs for rehabilitation and prevention of disabilities. Patients with disabilities need long-
term special treatment, physiotherapy and instruction in self-care awareness, so that a
reintegration in the social and working life is possible. The accessibility to local rehabilitation
centres must be guaranteed for every leprosy patient in any stage of the disease. According to
official instructions of the Brazilian Ministry of Health and of the State Health Secretariat of
Tocantins, every municipality is supposed to provide a specific room for physiotherapy.23
The long-term development of disabilities is reflected by the grade of disability (GD) at
diagnosis and later moments in time. In both examinations, 365 (58·0%) subjects presented
Grade 0 disability (G0D). However, the frequency of current G2D (9·1%) worsened
Table 4. Correlation between grade of disability (GD) at diagnosis (patient charts) and during study (clinical
examination)
GD at diagnosis (patient charts)
0* 1 2 Total
GD during study (clinical examination) N (%) N (%) N (%) N (%)
0* 365 (58·0) 86 (13·7) 6 (0·9) 457 (72·6)
1 71 (11·3) 36 (5·7) 8 (1·3) 115 (18·3)
2 23 (3·7) 20 (3·2) 14 (2·2) 57 (9·1)
Total 459 (73·0) 142 (22·6) 28 (4·4) 629 (100)
Light grey: Improvement of GD (diagnosis – time of study).
Dark grey: Worsening of GD (diagnosis – time of study).
To read cross tabulation: at diagnosis 459 (73·0%) patients had no impairments; at clinical examination during































Figure 1a/b. Absolute frequency of the subjects with G1D and G2D, stratified by gender and age group, at the time of
the study.
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considerably in comparison to G2D at diagnosis (4·4%). The distribution of individuals with
G1D showed a higher level in the current evaluation. This shows that the impairments
worsened during/after RFT and that secondary prevention measures need to be intensified.
In previous studies, a similar trend has been observed.12,24,25 In an Indonesian study, up to
5 years after RFT there was an increase from 31·0% at diagnosis to 49·0% of patients with
G2D.22 After RFT, the patients are usually out of the monitoring of the health services and not
followed up, but during this period leprosy-related sequelae mostly occur. Signs and
symptoms often cannot be interpreted correctly by the patients, resulting in delayed diagnosis
and treatment, and finally to developing of impairments. The follow-up of patients after RFT
has to be systematically integrated into the health services to ensure disease and morbidity
management, to instruct in awareness of the disease, and to respond immediately and
accordingly if leprosy related sequelae appear.12,26 Considering the chronic nature of leprosy,
these activities should continue, even when the incidence is decreasing. A recent study shows
considerable leprosy mortality in Brazil, despite the existence of a preventable and cost-
effective treatment. The authors emphasised that sustainable control measures should include
appropriate management and systematic monitoring of leprosy-related complications, such as
severe leprosy reactions and adverse effects to multidrug therapy.27 Early diagnosis, the
completion of MDT and adequate treatment of leprosy-related reactions prevent the
development of disabilities, so that the already existing programmes have to be intensified
with focus on these aspects.25 Furthermore, management, prevention, and socioeconomic
rehabilitation should be intensified to further prevent disabilities after RFT.12,22 Stigma-
related aspects should be considered to integrate people affected by leprosy-related
disabilities into the workplace and society.22,28,29
An additional finding in our study was the predominance of male subjects with
pathological results in the clinical examination. This observation coincides with other studies
from Brazil and elsewhere.22,24,29 – 32 Late diagnosis causes the occurrence of advanced
disease, including MB classification or already existing G1D or G2D. Reasons for delayed
diagnosis are multiple and may include fear of loss of social and economic life; e.g. loss of
work, as demonstrated in an Indian study.33 In general, late diagnosis is usually more
common in males, and the female population shows a more distinct health-seeking behaviour
as compared to males.12,29,31 Due to cultural and socioeconomic factors, Latin American men
are considered as the provider, the ‘stronger’ gender and invulnerable. In rural areas, reduced
geographic access to the health system may also be related to delayed diagnosis. Males also
often fail to attend consultations because of conflict with working hours. Therefore, several
Brazilian Health Care Programs extended the opening times (weekends and at night) of local
healthcare centres, with activities focused on the male population.32,34
The physical hard work, which in our study setting traditionally is more common in
males, comprises a higher risk for developing traumas and lesions especially after RFT,
increasing the risk of secondary disabilities in leprosy-affected individuals.35 In addition,
males have been shown to be less aware of disease-specific risks for disabilities.29 For
example, not wearing adequate shoes in case of loss of plantar sensibility may lead to plantar
ulcers36,37 or not interpreting leprosy-related symptoms correctly.38 A Brazilian study about
factors associated with delay in diagnosis revealed that nearly half of the participants did not
take their symptoms seriously.38 Independent of gender, it is important to intensify health
education measures to increase the awareness of the disease and to help interpreting leprosy-
related symptoms correctly.38
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In our study, advanced age was associated with higher risk of disabilities, independent
of gender. Similar results could be found in other studies.19,39 Relating to the chronic features of
leprosy, the risk of developing disabilities increases with duration of disease, and thus with age.12,19
Decentralisation of leprosy control programmes are known to improve case detection and to
reduce the number of treatment defaulters. In Brazil, the constant integration of leprosy control
into primary health care for several years, based on local municipal healthcare units, supports
the relationship and confidence between the health professionals and the patients.40 The local
healthcare centres are important for the day-to-day management relating to diagnosis and
treatment, improving early detection of the disease, of reactive episodes and of leprosy-related
sequelae. Decentralisation of the health system has also been recommended by WHO.41
Limitations
Incompleteness of secondary SINAN and patients’ health record data, mainly concerning
clinical variables at diagnosis (clinical form, operational classification and GD at diagnosis),
may have caused bias; the distributions of GD and gender at diagnosis and at the moment of
investigation are based on different population sizes and thus should be interpreted with care.
Professionals have to be trained in handling the information health systems and to manage,
report and process data collection.42
In this study, we focused on clinical examination of the upper and lower extremities,
because the interpretation of evaluation of the eyesight is limited, especially in difficult field
conditions43,44
Inter-observer variation may have occurred, especially regarding the clinical
examination. We aimed to minimise this error by applying intensive training and supervision
by experienced researchers and clinicians during data collection.
Conclusions
This study performed in a highly endemic area in Brazil shows that the presence of leprosy-
related disabilities after RFT is still common. Intensive longitudinal follow-up after RFT has
to be integrated systematically into the local health services to prevent the occurrence and
progression of disabilities. The access to management, prevention and rehabilitation of the
disabilities has to be intensified and guaranteed for every person affected by leprosy.
Difficult-to-reach-groups, e.g. working males and rural populations with difficult access to
the health system, have to be integrated more intensively into the focus of primary health
care. As the first contact people for the patient, professionals from local healthcare units must
be permanently trained in detecting leprosy and their sequelae and in transferring the data
correctly to the patients’ charts and datasets.
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